Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults
2014/05/30 by Sonata Jodele, Stella M. Davies, Adam Lane +14 · 26 citations
Immunology and Microbiology · Medicine · #Complement system in diseases #Renal Transplantation Outcomes and Treatments #Renal Diseases and Glomerulopathies
paper · doi:10.1182/blood-2014-03-564997
Abstract
Transplant-associated thrombotic microangiopathy (TMA) leads to generalized endothelial dysfunction that can progress to multiorgan injury, and severe cases are associated with poor outcomes after hematopoietic stem cell transplantation (HSCT). Identifying patients at highest risk for severe disease is challenging. We prospectively evaluated 100 consecutive HSCT recipients to determine the incidence of moderate and severe TMA and factors associated with poor overall outcomes. Thirty-nine subjects (39%) met previously published criteria for TMA. Subjects with TMA had a significantly higher nonrelapse mortality (43.6% vs 7.8%, P < .0001) at 1 year post-HSCT compared with those without TMA. Elevated lactate dehydrogenase, proteinuria on routine urinalysis, and hypertension were the earliest markers of TMA. Proteinuria (>30 mg/dL) and evidence of terminal complement activation (elevated sC5b-9) in the blood at the time of TMA diagnosis were associated with very poor survival (<20% at 1 year), whereas all TMA subjects without proteinuria and a normal sC5b-9 serum concentration survived (P < .01). Based on these prospective observations, we conclude that severe TMA occurred in 18% of HSCT recipients in our cohort and propose an algorithm to identify the highest-risk patients who might benefit from prompt clinical interventions.
Cited by
- Complement activation in secondary thrombotic microangiopathies
- Extra-renal manifestations of complement-mediated thrombotic microangiopathies. [europepmc]
- A new paradigm: Diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury. [europepmc]
- Histologic Features of Intestinal Thrombotic Microangiopathy in Pediatric and Young Adult Patients after Hematopoietic Stem Cell Transplantation. [europepmc]
- Variable Eculizumab Clearance Requires Pharmacodynamic Monitoring to Optimize Therapy for Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation. [europepmc]
- New approaches in the diagnosis, pathophysiology, and treatment of pediatric hematopoietic stem cell transplantation-associated thrombotic microangiopathy. [europepmc]
- Healthcare Burden, Risk Factors, and Outcomes of Mucosal Barrier Injury Laboratory-Confirmed Bloodstream Infections after Stem Cell Transplantation. [europepmc]
- Pathophysiology of GvHD and Other HSCT-Related Major Complications. [europepmc]
- Complement-mediated thrombotic microangiopathy as a link between endothelial damage and steroid-refractory GVHD. [europepmc]
- Pathogenesis of Atypical Hemolytic Uremic Syndrome. [europepmc]
- Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab. [europepmc]
- Complement in Thrombotic Microangiopathies: Unraveling Ariadne's Thread Into the Labyrinth of Complement Therapeutics. [europepmc]
- Transplant-Associated Thrombotic Microangiopathy Is a Multifactorial Disease Unresponsive to Immunosuppressant Withdrawal. [europepmc]
- Transplant-Associated Thrombotic Microangiopathy in Pediatric Hematopoietic Cell Transplant Recipients: A Practical Approach to Diagnosis and Management. [europepmc]
- Allogeneic reactivity-mediated endothelial cell complications after HSCT: a plea for consensual definitions. [europepmc]
- Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab. [europepmc]
- Incidence, Risk Factors for and Outcomes of Transplant-Associated Thrombotic Microangiopathy. [europepmc]
- Interferon-complement loop in transplant-associated thrombotic microangiopathy. [europepmc]
- Complementopathies and precision medicine. [europepmc]
- Microvascular thrombosis: experimental and clinical implications. [europepmc]
- Endothelial injury and thrombotic microangiopathy in COVID-19: Treatment with the lectin-pathway inhibitor narsoplimab. [europepmc]
- Evidence of thrombotic microangiopathy in children with SARS-CoV-2 across the spectrum of clinical presentations. [europepmc]
- A pragmatic multi-institutional approach to understanding transplant-associated thrombotic microangiopathy after stem cell transplant. [europepmc]
- Transplant-associated thrombotic microangiopathy: theoretical considerations and a practical approach to an unrefined diagnosis. [europepmc]
- Integrating CAR T-Cell Therapy and Transplantation: Comparisons of Safety and Long-Term Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation After CAR T-Cell or Chemotherapy-Based Complete Remission in B-Cell Acute Lymphoblastic Leukemia. [europepmc]
- Harmonizing Definitions for Diagnostic Criteria and Prognostic Assessment of Transplantation-Associated Thrombotic Microangiopathy: A Report on Behalf of the European Society for Blood and Marrow Transplantation, American Society for Transplantation and Cellular Therapy, Asia-Pacific Blood and Marrow Transplantation Group, and Center for International Blood and Marrow Transplant Research. [europepmc]
Related